Skip to main content
Caplight Logo









Biophytis SA

Biophytis SA

Public

Biophytis SA is now publicly traded

The data on this page reflects Biophytis SA's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Last Round

Seed Round

Sep 23, 2026

Total Funding Raised

$4.18M

Company Overview

Biophytis SA is a biotechnology company that develops drug candidates for the treatment of age-related diseases.

AI Layer

Application

Keywords

biotechnologydrug discoveryclinical-stage biotechsarcopenia treatmentDuchenne muscular dystrophysmall molecule drugage-related diseasetherapeutic compoundsclinical trialsdrug licensingAI drug discoverybiotech startuppharma pipelinelongevity biotech

Biophytis SA Comparables

Compare Biophytis SA with similar companies based on industry and business-model similarity.

No public comparables are available for Biophytis SA. Request access to learn about comparables coverage.

Request access

Biophytis SA Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Seed RoundSep 23, 2026
Seed RoundMar 23, 2026

Key People

Founding team and executive leadership

Stanislas Veillet

President and CEO

Executive Team

Christophe Courtillat

CFO

Executive Team

Biophytis SA Investors

Notable investors and investment history

Biophytis SA investors
InvestorRounds
Bigger CapitalSeed Round
Alumni Capital ManagementSeed Round

Biophytis SA Filings

Explore SEC and related filing metadata, where available.

Biophytis SA filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Firmographic Details

HeadquartersParis
Employee Range24
Year Founded2006
Last FundingSep 23, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?